The stem cell company NextCell Pharma participates as a reference laboratory in NIBSC study
NextCell Pharma AB ("NextCell") announces today, that it has acted as a reference laboratory to assist National Institute for Biological Standards and Control (NIBSC) in the development of a reference reagent for Mesenchymal Stem
The NIBSC is a UK based entity and a global leader when it comes to the characterisation, standardisation and control of biological medicines. As part of their activities the NIBSC has been endorsed by the World Health Organization (WHO) to develop and generate a reference for MSCs. The official name of the study/assignment is: “International Collaborative Study to Evaluate a Candidate WHO Mesenchymal Stem Cell Flow Cytometry Reference Reagent”.
NIBSC plays a major role in assuring the quality of biological medicines worldwide through the provision of biological reference materials, by testing products and carrying out research. NextCell’s drug candidate ProTrans, is based on MSC and therefore, NextCell was asked by NIBSC to evaluate the reference reagent.
Based on the input of NextCell and the other reference centres the NIBSC will produce a report for the WHO and if everything goes according to plan the WHO will approve the reagent, and the product will become available for all labs to use as a reference material. This is something which can be of great value for any entity actively working with MSCs. NextCell’s contribution is limited to the testing of the supplied materials and will not acquire any product/rights but will be listed as a project participant and by participating will gain access to additional knowledge, capabilities and networks.
Stay up to date with the latest development in NextCell Pharma
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com
About NextCell Pharma AB:
Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell
Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Scandinavia´s largest stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.